查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067692

特種非專利市場規模、佔有率和趨勢分析報告：按類型、適應症、最終用途、地區和細分市場預測（2026-2033 年）

Specialty Generics Market Size, Share & Trends Analysis Report By Type (Injectables, Oral Drugs), By Indication (Oncology, Inflammatory conditions, Multiple sclerosis, Hepatitis C), By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

特藥非專利市場概述

2025年全球特藥非專利市場規模估計為959.8億美元，預計2033年將達到1,713.6億美元。

預計從 2026 年到 2033 年，該市場將以 7.58% 的複合年成長率成長。受慢性病和罕見疾病負擔加重以及對經濟有效的治療方案的需求推動，該市場正在穩步成長。

這些藥物在使複雜治療方法更容易患者獲得方面發揮著至關重要的作用，尤其是在腫瘤、自體免疫疾病和感染疾病。製劑技術的進步和監管機構對學名藥核准的支持進一步推動了市場擴張。此外，對生物相似藥和高價值注射學名藥的日益關注正在重塑競爭格局。隨著醫療保健系統將可負擔性和可近性置於優先地位，學名藥正成為永續醫療保健的重要組成部分。

根據世界衛生組織（世衛組織）的數據，全球老年人口正在快速成長，近年來成長尤為顯著。預計到2030年，老年人口佔總人口的比例將大幅上升，屆時每六個人中就有一人年齡在60歲或以上。由於老年人更容易患上需要長期治療的慢性複雜疾病，這種人口結構的變化預計將為特藥非專利市場帶來巨大的成長機會。此外，領先企業正日益重視併購和策略聯盟，以鞏固其市場地位並拓展其特藥學名藥產品組合。這些舉措預計將在預測期內推動市場持續成長。

然而，消費者對原廠藥的強烈品牌忠誠度、專科學名藥研發和生產的複雜要求以及相對較低的利潤率，都對新參與企業市場構成了重大障礙。這些挑戰可能導致某些細分市場競爭有限，並加劇價格壓力。此外，原廠藥生產商的病患支援計畫和促銷策略往往鼓勵病患繼續使用原廠藥，這反過來又會影響專科學名藥的普及和市場滲透率。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：特藥非專利市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：特藥非專利市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 注射藥物
  • 口服藥物
  • 其他

第5章：專科非專利市場：按適應症分類的業務分析

  • 按適應症分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 腫瘤學
  • 發炎性疾病
  • 多發性硬化症
  • C型肝炎
  • 其他

第6章：專科非專利市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測和趨勢分析：按最終用途分類，2021-2033 年
  • 專科藥房
  • 零售藥房
  • 醫院藥房

第7章：特藥非專利市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Teva Pharmaceuticals Industries Ltd
    • Viatris Inc.
    • Novartis AG（Sandoz International GmbH）
    • Hikma Pharmaceuticals PLC.
    • Mallinckrodt
    • Bausch Health Companies Inc.（Valeant Pharmaceuticals International, Inc.）
    • Dr. Reddy's Laboratories Ltd.
    • Endo Pharmaceuticals Inc.
    • Apotex Corp.
    • Sun Pharmaceutical Industries Ltd
Product Code: GVR-1-68038-629-5

Specialty Generics Market Summary

The global specialty generics market size was estimated at USD 95.98 billion in 2025 and is projected to reach USD 171.36 billion by 2033, growing at a CAGR of 7.58% from 2026 to 2033. The market is witnessing steady growth driven by the rising burden of chronic and rare diseases and the demand for cost-effective treatment alternatives.

These drugs play a crucial role in improving patient access to complex therapies, particularly in oncology, autoimmune disorders, and infectious diseases. Advancements in drug formulation technologies and regulatory support for generic approvals are further facilitating market expansion. Additionally, the growing focus on biosimilars and high-value injectable generics is reshaping the competitive landscape. As healthcare systems emphasize affordability and accessibility, specialty generics are emerging as a key component of sustainable pharmaceutical care.

According to the World Health Organization (WHO), the global geriatric population is expanding rapidly, rising significantly in recent years, and is projected to reach a substantial share of the total population by 2030, with one in six individuals aged 60 years and above. This demographic shift is expected to create significant growth opportunities in the specialty generics market, as older populations are more prone to chronic and complex diseases that require long-term treatment. In addition, leading pharmaceutical companies are increasingly focusing on mergers, acquisitions, and strategic collaborations to strengthen their market presence and expand their specialty generics portfolios. Such initiatives are anticipated to support sustained market growth over the forecast period.

However, strong brand loyalty toward innovator drugs, the complex development and manufacturing requirements of specialty generics, and relatively lower profit margins act as significant entry barriers for new market participants. These challenges can contribute to limited competition and pricing pressures in certain segments. Furthermore, patient assistance programs and promotional strategies adopted by branded drug manufacturers often enhance patient retention for original products, thereby impacting the uptake and market penetration of specialty generic alternatives.

Global Specialty Generics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global specialty generics market report based on type, indication, end use, and region:

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Injectables
  • Oral drugs
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oncology
  • Inflammatory conditions
  • Multiple sclerosis
  • Hepatitis C
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Specialty pharmacy
  • Retail pharmacy
  • Hospital pharmacy
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Indication
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market End Use & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Specialty Generics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Specialty Generics Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
  • 4.4. Injectables
    • 4.4.1. Injectables Market, 2021 - 2033 (USD Billion)
  • 4.5. Oral Drugs
    • 4.5.1. Oral Drugs Market, 2021 - 2033 (USD Billion)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Specialty Generics Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2021 - 2033 (USD Billion)
  • 5.5. Inflammatory Conditions
    • 5.5.1. Inflammatory Conditions Market, 2021 - 2033 (USD Billion)
  • 5.6. Multiple Sclerosis
    • 5.6.1. Multiple Sclerosis Market, 2021 - 2033 (USD Billion)
  • 5.7. Hepatitis C
    • 5.7.1. Hepatitis C Market, 2021 - 2033 (USD Billion)
  • 5.8. Others
    • 5.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Specialty Generics Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2025 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
  • 6.4. Specialty Pharmacy
    • 6.4.1. Specialty Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.6. Hospital Pharmacy
    • 6.6.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)

Chapter 7. Specialty Generics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Specialty Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Teva Pharmaceuticals Industries Ltd
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Viatris Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novartis AG (Sandoz International GmbH)
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Hikma Pharmaceuticals PLC.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Mallinckrodt
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dr. Reddy's Laboratories Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Endo Pharmaceuticals Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Apotex Corp.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Type Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Sun Pharmaceutical Industries Ltd
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Type Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global specialty generics market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 5 Global specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 6 Global specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 7 North America specialty generics market, by country, 2021 - 2033 (USD Billion)
  • Table 8 North America specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 9 North America specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 10 North America specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 11 U.S specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 12 U.S specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 13 U.S specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 14 Canada specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 15 Canada specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 16 Canada specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 17 Mexico specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 18 Mexico specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 19 Mexico specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 20 Europe specialty generics market, by country, 2021 - 2033 (USD Billion)
  • Table 21 Europe specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 22 Europe specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 23 Europe specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 24 UK specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 25 UK specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 26 UK specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 27 Germany specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 28 Germany specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 29 Germany specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 30 France specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 31 France specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 32 France specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 33 Italy specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 34 Italy specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 35 Italy specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 36 Spain specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 37 Spain specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 38 Spain specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 39 Norway specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 40 Norway specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 41 Norway specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 42 Denmark specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 43 Denmark specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 44 Denmark specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 45 Sweden specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 46 Sweden specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 47 Sweden specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific specialty generics market, by country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 52 Japan specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 53 Japan specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 54 Japan specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 55 China specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 56 China specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 57 China specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 58 India specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 59 India specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 60 India specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 61 Australia specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 62 Australia specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 63 Australia specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 64 South Korea specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 65 South Korea specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 66 South Korea specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 67 Thailand specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 68 Thailand specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 69 Thailand specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 70 Latin America specialty generics market, by country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 72 Latin America specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 73 Latin America specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 74 Brazil specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 75 Brazil specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 76 Brazil specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 77 Argentina specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 78 Argentina specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 79 Argentina specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa specialty generics market, by country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 82 Middle East specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 84 South Africa specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 85 South Africa specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 86 South Africa specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 90 UAE specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 91 UAE specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 92 UAE specialty generics market, by end use, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait specialty generics market, by type, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait specialty generics market, by indication, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait specialty generics market, by end use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Specialty Generics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market end use & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Specialty Generics market dynamics
  • Fig. 11 Specialty Generics market: Porter's five forces analysis
  • Fig. 12 Specialty Generics market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Billion)
  • Fig. 14 Injectables market, 2021 - 2033 (USD Billion)
  • Fig. 15 Oral drugs market, 2021 - 2033 (USD Billion)
  • Fig. 16 Others market, 2021 - 2033 (USD Billion)
  • Fig. 17 Indication market, 2021 - 2033 (USD Billion)
  • Fig. 18 Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 19 Inflammatory conditions market, 2021 - 2033 (USD Billion)
  • Fig. 20 Multiple sclerosis market, 2021 - 2033 (USD Billion)
  • Fig. 21 Hepatitis C market, 2021 - 2033 (USD Billion)
  • Fig. 22 Others market, 2021 - 2033 (USD Billion)
  • Fig. 23 End Use market, 2021 - 2033 (USD Billion)
  • Fig. 24 Specialty pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 25 Retail pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 26 Hospital pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 27 Specialty Generics market revenue, by region
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 36 Europe Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 41 France country dynamics
  • Fig. 42 France Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 53 Asia Pacific Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 56 China country dynamics
  • Fig. 57 China Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 58 India country dynamics
  • Fig. 59 India Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 66 Latin America Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 71 MEA Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait Specialty Generics market, 2021 - 2033 (USD Billion)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework